Gemphire Therapeutics Inc. (GEMP)’s Trend Down, Especially After Today’s All-Time Low

The stock of Gemphire Therapeutics Inc. (NASDAQ:GEMP) reached all time low today, Aug, 15 and still has $0.51 target or 8.00 % below today’s $0.55 share price. This indicates more downside for the $8.18 million company. This technical setup was reported by Barchart.com. If the $0.51 PT is reached, the company will be worth $654,400 less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only.

The stock decreased 13.74% or $0.0876 during the last trading session, reaching $0.55. About 173,765 shares traded. Gemphire Therapeutics Inc. (NASDAQ:GEMP) has declined 91.55% since August 15, 2018 and is downtrending. It has underperformed by 91.55% the S&P500.

More notable recent Gemphire Therapeutics Inc. (NASDAQ:GEMP) news were published by: Seekingalpha.com which released: “Gemphire down 6% on uneven results from POC study of gemcabene – Seeking Alpha” on June 26, 2019, also Benzinga.com with their article: “33 Healthcare Stocks Moving In Today’s Pre-Market Session – Benzinga” published on July 30, 2019, Seekingalpha.com published: “Gemphire And Gemcabene: The Orphan First Approach Is An Excellent Clinical Refocus – Seeking Alpha” on May 27, 2019. More interesting news about Gemphire Therapeutics Inc. (NASDAQ:GEMP) were released by: Seekingalpha.com and their article: “Gemphire Therapeutics And Gemcabene:The Costly Delay – Seeking Alpha” published on January 27, 2019 as well as Benzinga.com‘s news article titled: “A Look At Benzinga Pro’s Most-Searched Tickers For July 26, 2019 – Benzinga” with publication date: July 26, 2019.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis . The company has market cap of $8.18 million. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. It currently has negative earnings.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.